STUDY OF ENCORAFENIB + CETUXIMAB PLUS OR MINUS BINIMETINIB VS. IRINOTECAN/CETUXIMAB OR INFUSIONAL 5-FLUOROURACIL (5-FU)/FOLINIC ACID (FA)/IRINOTECAN (FOLFIRI)/CETUXIMAB WITH A SAFETY LEAD-IN OF ENCORAFENIB + BINIMETINIB + CETUXIMAB IN PATIENTS WITH BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER: